Innovative Approaches in Weight Loss Therapy

Sky Bioscience is conducting a Phase 2 clinical trial for a new weight loss therapeutic, nimasumab, which targets peripheral CB1 inhibition. This trial aims to assess its safety and efficacy in reducing weight for patients with obesity while considering additional health outcomes such as gastrointestinal tolerability and muscle retention. It involves enrolling 120 patients across four treatment groups to evaluate the drug's effects compared to a placebo and GLP-1 based treatments. The trial's design reflects a growing need for alternative weight loss solutions that provide better overall health results and sustainability beyond traditional therapies.